Results 101 to 110 of about 19,009 (196)
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Comparison of P15ink4b methylation before and after decitabine regimens.
p15 methylation level decreased after decitabine treatment in responders (n = 41) (A); p15 methylation level elevated slightly after decitabine treatment in nonresponders (n = 18) (B).
Xi Zhang (83736) +12 more
core +1 more source
Decitabine reduced GFP-positive rates (%GFP) in transduced human CD34+ cells.
(a). Human CD34+ cells were cultured in serum-free media containing cytokines (SCF, FLT3L, and TPO). After 24 hours of prestimulation, the cells were transduced with GFP-expressing HIV-1 based lentiviral vectors for 24 hours.
Yogen Saunthararajah (320626) +4 more
core +1 more source
The epigenetic drug Decitabine is a cytidine nucleoside analog DNA methyltransferase inhibitor that is used in the treatment of myelodysplastic syndrome (MDS) and leukemia and is being investigated in the treatment of numerous other cancers and diseases.
Tselenchuk, Dimitri
core
Study Design: Platinum resistant ovarian cancer subjects treated with decitabine and carboplatin.
Fourteen platinum resistant ovarian cancer patients were treated with decitabine/carboplatin in a phase II clinical trial. For the first chemotherapy cycle, decitabine was given daily for 5 days; followed by carboplatin given on day 8.
Kenneth P. Nephew (212536) +4 more
core +1 more source
The Mouse Mammary Tumor Virus Mediates the Antineoplastic Action of Decitabine [PDF]
The purpose of this study is to clarify the role of the mouse mammary tumor virus (MMTV) in the antineoplastic effect of decitabine, a DNA demethylating agent.
Brola, Andrew
core +2 more sources
Alessandra Di Costanzo, Luca Loreto, Chiara Vassallo, Francesca Fiorentino Real World Solutions, IQVIA Solutions Italy S.r.l., Milan, ItalyCorrespondence: Chiara Vassallo, Real World Solutions, IQVIA Solutions Italy s.r.l., Via Fabio Filzi 29, Milan ...
Di Costanzo A +3 more
doaj
Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression, with limited targeted therapies and poor outcomes. Epigenetic dysregulation, particularly aberrant DNA methylation, is a key driver.
Fathima Raahima Riyas Mohamed +9 more
core +1 more source
New decitabine nanoparticle formulations to acute myeloid leukemia treatments
Ces travaux de thèse ont porté sur le développement de formulations innovantes et nanoparticulaire, destinées à améliorer la prise en charge des patients atteints de leucémie aigüe myéloïdes (LAM).
Briot, Thomas
core

